185 related articles for article (PubMed ID: 38020782)
1. Serum zinc deficiency is a potential risk factor for the occurrence of levodopa-induced dyskinesia in drug-naïve Parkinson's disease.
Kim JE; Lee HS; Jang W
Front Aging Neurosci; 2023; 15():1282367. PubMed ID: 38020782
[TBL] [Abstract][Full Text] [Related]
2. Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia.
Jeong EH; Sunwoo MK; Song YS
Front Neurol; 2018; 9():1133. PubMed ID: 30619078
[No Abstract] [Full Text] [Related]
3. Serum zinc deficiency could be associated with dementia conversion in Parkinson's disease.
Lee J; Park S; Jang W
Front Aging Neurosci; 2023; 15():1132907. PubMed ID: 37181629
[TBL] [Abstract][Full Text] [Related]
4. Association of metals with the risk and clinical characteristics of Parkinson's disease.
Kim MJ; Oh SB; Kim J; Kim K; Ryu HS; Kim MS; Ayton S; Bush AI; Lee JY; Chung SJ
Parkinsonism Relat Disord; 2018 Oct; 55():117-121. PubMed ID: 29891430
[TBL] [Abstract][Full Text] [Related]
5. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
[TBL] [Abstract][Full Text] [Related]
6. White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease.
Chung SJ; Yoo HS; Lee YH; Jung JH; Baik K; Ye BS; Sohn YH; Lee PH
Ann Clin Transl Neurol; 2020 Feb; 7(2):229-238. PubMed ID: 32032471
[TBL] [Abstract][Full Text] [Related]
7. High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.
Shiraishi T; Nishikawa N; Mukai Y; Takahashi Y
Parkinsonism Relat Disord; 2020 Jun; 75():80-84. PubMed ID: 32497995
[TBL] [Abstract][Full Text] [Related]
8. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease.
Yang Y; Cheon M; Kwak YT
Dement Neurocogn Disord; 2017 Sep; 16(3):57-63. PubMed ID: 30906372
[TBL] [Abstract][Full Text] [Related]
9. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
[TBL] [Abstract][Full Text] [Related]
10. Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson's disease.
Jung JH; Chung SJ; Yoo HS; Lee YH; Baik K; Ye BS; Sohn YH; Lee PH
Eur J Neurol; 2020 Oct; 27(10):1948-1956. PubMed ID: 32441832
[TBL] [Abstract][Full Text] [Related]
11. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
[TBL] [Abstract][Full Text] [Related]
12. Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.
Martinez-Carrasco A; Real R; Lawton M; Iwaki H; Tan MMX; Wu L; Williams NM; Carroll C; Hu MTM; Grosset DG; Hardy J; Ryten M; Foltynie T; Ben-Shlomo Y; Shoai M; Morris HR
medRxiv; 2023 May; ():. PubMed ID: 37425912
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
Dias CMV; Leal DAB; Brys I
Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453
[No Abstract] [Full Text] [Related]
14. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
15. Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia.
Sosero YL; Bandres-Ciga S; Ferwerda B; Tocino MTP; Belloso DR; Gómez-Garre P; Faouzi J; Taba P; Pavelka L; Marques TM; Gomes CPC; Kolodkin A; May P; Milanowski LM; Wszolek ZK; Uitti RJ; Heutink P; van Hilten JJ; Simon DK; Eberly S; Alvarez I; Krohn L; Yu E; Freeman K; Rudakou U; Ruskey JA; Asayesh F; Menéndez-Gonzàlez M; Pastor P; Ross OA; Krüger R; Corvol JC; Koks S; Mir P; De Bie RMA; Iwaki H; Gan-Or Z
medRxiv; 2023 Sep; ():. PubMed ID: 37790572
[TBL] [Abstract][Full Text] [Related]
16. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
17. Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.
Yoo HS; Lee EC; Chung SJ; Ye BS; Sohn YH; Seong JK; Lee PH
Sci Rep; 2022 Jul; 12(1):12631. PubMed ID: 35879381
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
Kwon DK; Kwatra M; Wang J; Ko HS
Cells; 2022 Nov; 11(23):. PubMed ID: 36496996
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Dyskinesia in Parkinson's Disease in Mainland China.
Zhou X; Guo J; Sun Q; Xu Q; Pan H; Yu R; Tan J; Yan X; Tang B; Fang L
Front Neurol; 2019; 10():477. PubMed ID: 31164859
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
